ReviewThe roles of adenosine deaminase in autoimmune diseases
Introduction
Autoimmune diseases are a complicated set of chronic diseases with unknown etiology, which are characterized by autoimmune tolerance deficiency. The imbalance of innate and adaptive immunity have been found to play important roles during autoimmune diseases progression [[1], [2], [3], [4]]. Immune system of autoimmune disease patients cannot distinguish self-antigens from foreign antigens, which leads to the abnormal immune response against self-tissues and organs. Thus, abundant autoantibodies were appeared in serum and organs of patients with autoimmune diseases [5,6]. Autoimmune diseases can be classified into organ-specific and systemic autoimmune diseases according to the location of lesions involved. Organ-specific autoimmune diseases means that lesions are confined to specific tissues or organs, such as myasthenia gravis (MG), ulcerative colitis (UC), primary biliary cirrhosis (PBC), etc. Systemic autoimmune diseases means that lesions can involve a variety of tissues and organs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), dermatomyositis (JM), etc. Up to date, most types of the autoimmune diseases still lack the efficient laboratory markers. At present, there are several conventional markers commonly used in clinical, such as autoantibody, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Rheumatoid factor (RF). However, the specificity or sensitivity of these marker were still unsatisfactory. As an immune regulatory molecule, adenosine deaminase (ADA) has showed the potential clinical value in diagnosis and monitoring of autoimmune diseases.
Section snippets
Adenosine deaminase
ADA is an important immune regulatory molecule, which play an important role in maturation and maintenance of immune system [7,8]. It has well known that ADA deficiency could result to human severe combined immunodeficiency (SCID). SCID due to ADA deficiency was the first inherited disease treated with a gene transfer therapy approach [9,10]. Since the ADA deficiency could result to the immunodeficiency, then how are the effects or clinical significances of elevated ADA activity in human
ADA activity in SLE
SLE is a systemic and potentially also life-threatening autoimmune disease with unknown etiology, which affects almost all the tissues and organs, including skin, kidney, arthrosis, etc. SLE is more common in young and middle-aged women. Immune overreaction is an key factor and feature for SLE development, thus, immunosuppressive therapy is still a common treatment for SLE patients [32]. Saghiri R and colleagues have showed the elevated serum tADA and ADA2 activity in SLE patients compared with
ADA activity in rheumatoid arthritis
rheumatoid arthritis (RA) is a common chronic autoimmune disease with unknown etiology, which is characterized by joint destruction and inflammatory synovitis. The changes of ADA activity in RA patients were inconsistent from different studies (Table 2). Several studies have showed that ADA were increased in RA patients, while ours study showed that tADA, ADA1 and ADA2 activities were all not different between RA patients and age & sex matched healthy controls [38]. In addition, the reports of
ADA activity in juvenile idiopathic arthritis
Juvenile idiopathic arthritis (JIA) covers a heterogeneous group of connective tissue diseases which are similar in onset which is before the age of 16 and that they last for at least 6 weeks. According to the clinical feature, JIA patients were categorized into these subtypes: systemic JIA (sJIA), oligoarthritis, ployarthritis, enthesitis Related JIA (ERA), psoriatic JIA and undefined JIA. There were few studies about the ADA activity in JIA patients. Hitoglou S and colleagues showed that
ADA activity in AILD
AILD constitutes a group of chronic inflammatory diseases with unknown etiology and pathophysiology, and characterized by hyperglobulinemia, presence of auto-antibodies, and inflammation within the liver. Primary Biliary Cirrhosis (PBC), Autoimmune Hepatitis (AIH), and Primary Sclerosing Cholangitis (PSC) are the classic types of AILD. Torgutalp M and colleagues have showed that ADA activity were significantly higher and was correlated with inflammatory activity in AIH patients [25]. In our
ADA activity in Adult-Onset Still's Disease
Adult-onset Still's disease (AOSD) is a systemic inflammatory disorder with unknown etiology, characterized by fever, rash, arthritis, and neutrophilic leucocytosis, etc. There are no specific diagnostic indexes for AOSD. Pubmed were searched using the terms “ADA, adult-onset Still's disease”. Only one report in 2013 by Xun C and colleagues studied the potential role of ADA activity in AOSD diagnosis. Theirs study showed that ADA activity was higher in AOSD patients than that in SLE and healthy
Systemic sclerosis
Systemic sclerosis (SSc) is a rare chronic systemic autoimmune disease of unknown etiology, characterized by vascular abnormalities and fibrosis involving the skin and internal organs, such as the gastrointestinal tract, lung, heart and kidneys. Sasaki T showed that serum ADA activity was increased in patients with progressive systemic sclerosis (PSS) [42]. And furthermore, Meunier P and colleagues found that plasma ADA activity were higher in patients with PSS involvement of the skin and other
ADA activity in autoimmune diseases of the nervous system
It is well known that ADA activity is increased in CSF of patients with tubercular meningitis (TBM) and has been used for differential diagnosis of TBM. In this paper, we analyzed the literatures to reveal that whether the ADA activity was changed in autoimmune diseases of the nervous system.
Summary
In summary, ADA activity are increased in several types of autoimmune disease. The measure of ADA activity would be helpful in clinical diagnosis or disease activity monitoring.
Funding
This work is supported by the Basic Research Program of Natural Science of Shaanxi Province (2020JM-315).
Declaration of Competing Interest
The authors declare that they have no conflict of interest.
References (51)
- et al.
The yin and Yang of regulatory T cell and therapy progress in autoimmune disease
Autoimmun Rev
(2017) - et al.
NK cells in autoimmune diseases: linking innate and adaptive immune responses
Autoimmun Rev
(2018) - et al.
Autoantibodies in pre-clinical autoimmune disease
Clin Chim Acta
(2014) - et al.
Diagnostic test accuracy of adenosine deaminase for tuberculous meningitis: a systematic review and meta-analysis
J Infect
(2017) - et al.
Elevated serum adenosine deaminase levels in secondary hemophagocytic lymphohistiocytosis
Int J Lab Hematol
(2015) - et al.
Adenosine signaling and the immune system: when a lot could be too much
Immunol Lett
(2019) - et al.
Differential expression of adenosine deaminase isozymes in acute leukemia
Blood.
(1988) - et al.
Serum adenosine deaminase activity in systemic sclerosis (scleroderma) and related disorders
J Am Acad Dermatol
(1992) - et al.
The role of the adenosinergic system in lung fibrosis
Pharmacol Res
(2013) - et al.
Alterations in the cholinesterase and adenosine deaminase activities and inflammation biomarker levels in patients with multiple sclerosis
Neuroscience.
(2014)
Multiple sclerosis showing elevation of adenosine deaminase levels in the cerebrospinal fluid
Mult Scler Relat Disord
High serum adenosine deaminase activity and its correlation with lymphocyte subsets in myasthenia gravis
J Neurol Sci
The role of monocytes and macrophages in autoimmune diseases: a comprehensive review
Front Immunol
Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies
Immunol Rev
Autoantibodies in autoimmune diseases: clinical and critical evaluation
Isr Med Assoc J
Adenosine deaminase deficiency - more than just an immunodeficiency
Front Immunol
Adenosine deaminase in the modulation of immune system and its potential as a novel target for treatment of inflammatory disorders
Curr Drug Targets
Gene therapy for adenosine deaminase deficiency
Curr Opin Allergy Clin Immunol
Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products
EMBO Mol Med
Diagnostic accuracy of cerebrospinal fluid adenosine deaminase in detecting tuberculous meningitis
Pak J Med Sci
Diagnostic value of adenosine deaminase in cerebrospinal fluid for tuberculous meningitis: a meta-analysis
Int J Tuberc Lung Dis
Pleural fluid adenosine deaminase (ADA) predicts survival in patients with malignant pleural effusion
Lung.
Increased pleural fluid adenosine deaminase levels in patients with malignant pleural effusions: a potential predictor of talc pleurodesis outcome
Lung.
Adenosine deaminase for diagnosis of tuberculous pleural effusion: a systematic review and meta-analysis
PLoS One
Diagnostic value of pleural effusion mononuclear cells count and adenosine deaminase for tuberculous pleurisy patients in china: a case-control study
Front Med (Lausanne)
Cited by (40)
The potential of CD38 protein as a target for autoimmune diseases
2023, Autoimmunity ReviewsAmbient air pollution and inflammation-related proteins during early childhood
2022, Environmental ResearchCitation Excerpt :Emerging evidence suggests the role of air pollution in autoimmune diseases (Zhao et al., 2019). In the present study, we observed association of air pollution exposure with ADA, a degrading enzyme for an immunosuppressive signal, adenosine, playing an important role in immune homeostasis regulation and autoimmune diseases development (Gao et al., 2021). The biomarkers FGF-23, uPA and TRAIL identified in our study represent novel associations in the context of air pollution, thus contributing to the growing body of evidence documenting inflammatory effects of human exposure to air pollution.